Should I buy or sell CalciMedica stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CalciMedica in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CALC shares. View CALC analyst ratings or view top-rated stocks .

What is CalciMedica's stock price target for 2024?

3 equities research analysts have issued 1 year target prices for CalciMedica's stock. Their CALC share price targets range from $14.00 to $22.00. On average, they expect the company's stock price to reach $18.67 in the next year. This suggests a possible upside of 364.3% from the stock's current price. View analysts price targets for CALC or view top-rated stocks among Wall Street analysts .

How have CALC shares performed in 2024?

CalciMedica's stock was trading at $2.86 on January 1st, 2024. Since then, CALC stock has increased by 40.6% and is now trading at $4.02. View the best growth stocks for 2024 here .

Are investors shorting CalciMedica?

CalciMedica saw a increase in short interest in March. As of March 31st, there was short interest totaling 37,200 shares, an increase of 318.0% from the March 15th total of 8,900 shares. Based on an average daily volume of 22,100 shares, the short-interest ratio is presently 1.7 days. Currently, 0.8% of the company's stock are short sold. View CalciMedica's Short Interest .

When is CalciMedica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CALC earnings forecast .

How do I buy shares of CalciMedica?

Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CALC

CalciMedica (CALC) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CALC Stock Alerts

$4.02

-0.32 (-7.37%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.01
▼
$4.19
50-Day Range: $3.39
▼
$5.80
52-Week Range: $1.75
▼
$8.59

Volume: 1,985 shs
Average Volume: 21,237 shs
Market Capitalization: $43.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Get CalciMedica alerts:

CalciMedica MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 364.3% Upside
$18.67 Price Target
Short Interest: Healthy
0.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$3.42 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.04) to ($1.99) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.18 out of 5 stars

Medical Sector

528th out of 918 stocks

Pharmaceutical Preparations Industry

230th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
CalciMedica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
CalciMedica has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.79% of the float of CalciMedica has been sold short.
Short Interest Ratio / Days to Cover
CalciMedica has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CalciMedica has recently increased by 317.98%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CalciMedica does not currently pay a dividend.
Dividend Growth
CalciMedica does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CALC.

0.6

News and Social Media Coverage

MarketBeat Follows
2 people have added CalciMedica to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CalciMedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,417,047.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
53.30% of the stock of CalciMedica is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CalciMedica are expected to grow in the coming year, from ($2.04) to ($1.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CalciMedica is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CalciMedica is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CalciMedica has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About CalciMedica Stock (NASDAQ:CALC)

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

CALC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CALC Stock News Headlines

April 3, 2024 | msn.com

CalciMedica And 2 Other Penny Stocks Insiders Are Buying

March 28, 2024 | finance.yahoo.com

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 13, 2024 | prnewswire.com

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

February 28, 2024 | finance.yahoo.com

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

February 24, 2024 | msn.com

SeaStar’s device granted humanitarian exemption approval for children with AKI

February 24, 2024 | msn.com

CalciMedica (CALC) Price Target Increased by 61.73% to 16.70

February 20, 2024 | it.investing.com

Singular Research alza il target del titolo CalciMedica a 9,50 dollari in presenza di un nuovo fondo

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

February 19, 2024 | ca.investing.com

CalciMedica stock target raised to $9.50 by Singular Research amid new fund

February 14, 2024 | msn.com

CalciMedica given FDA approval for Phase II trial of Auxora

February 14, 2024 | markets.businessinsider.com

CalciMedica’s Auxora Braces for Phase 2 Trial with Strong Buy Rating from Analyst Joseph Pantginis

February 13, 2024 | markets.businessinsider.com

CalciMedica Announces FDA Clearance Of IND Application For Phase 2 Trial Of Auxora

February 7, 2024 | finance.yahoo.com

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

January 28, 2024 | msn.com

Huge Insider Buys From Warren Buffett, Jack Ma, Carlos Slim and More

January 22, 2024 | markets.businessinsider.com

CalciMedica Announces Private Offering For Up To About $55 Mln; Stock Down In Pre-market

January 22, 2024 | marketwatch.com

CalciMedica Shares Rally After Funding Lined Up for Lead Product Candidate

January 22, 2024 | finance.yahoo.com

CalciMedica Announces Private Placement of up to Approximately $55 Million

December 11, 2023 | finance.yahoo.com

CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition

November 9, 2023 | msn.com

CalciMedica GAAP EPS of -$0.82

November 9, 2023 | finance.yahoo.com

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

November 8, 2023 | msn.com

CalciMedia CEO discloses purchase of 2K shares

November 7, 2023 | msn.com

CalciMedica chief business officer discloses purchase of about 9k shares

November 2, 2023 | finance.yahoo.com

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

September 6, 2023 | finance.yahoo.com

CalciMedica Announces Upcoming Presentations and Events in September

August 31, 2023 | finance.yahoo.com

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

August 11, 2023 | finance.yahoo.com

CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

See More Headlines

Receive CALC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CalciMedica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CALC
CUSIP: N/A
CIK: 1534133
Web: www.graybug.vision
Phone: 858-952-5500
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.67
High Stock Price Target: $22.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +364.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($25.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,360,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -234.70%
Return on Assets: -165.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.88
Quick Ratio: 2.88

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.42 per share
Price / Book: 2.83

Miscellaneous

Outstanding Shares: 10,740,000
Free Float: 5,016,000
Market Cap: $43.17 million
Optionable: No Data
Beta: 1.61

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. A. Rachel Leheny Ph.D. (Age 61)
CEO & Director
Mr. Eric W. Roberts (Age 60)
Chief Business Officer & Vice Chairman of the Board
Mr. Michael J. Dunn MBA (Age 68)
President & COO
Dr. Anjana Rao Ph.D.
Co-Founder and Scientific Advisor
Dr. Patrick Hogan Ph.D.
Co-Founder and Scientific Advisor
Dr. Stefan Feske M.D.
Co-Founder and Scientific Advisor
Dr. Kenneth A. Stauderman Ph.D. (Age 71)
Co-Founder & Chief Scientific Officer
Mr. Daniel E. Geffken M.B.A. (Age 67)
Interim Chief Financial Officer
Cindy Reiedenberg
Accountant
Mr. John M. Dunn J.D. (Age 72)
General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CALC Stock Analysis - Frequently Asked Questions

Should I buy or sell CalciMedica stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CalciMedica in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CALC shares.
View CALC analyst ratings or view top-rated stocks.
What is CalciMedica's stock price target for 2024?: 3 equities research analysts have issued 1 year target prices for CalciMedica's stock. Their CALC share price targets range from $14.00 to $22.00. On average, they expect the company's stock price to reach $18.67 in the next year. This suggests a possible upside of 364.3% from the stock's current price.
View analysts price targets for CALC or view top-rated stocks among Wall Street analysts.
How have CALC shares performed in 2024?: CalciMedica's stock was trading at $2.86 on January 1st, 2024. Since then, CALC stock has increased by 40.6% and is now trading at $4.02.
View the best growth stocks for 2024 here.
Are investors shorting CalciMedica?: CalciMedica saw a increase in short interest in March. As of March 31st, there was short interest totaling 37,200 shares, an increase of 318.0% from the March 15th total of 8,900 shares. Based on an average daily volume of 22,100 shares, the short-interest ratio is presently 1.7 days. Currently, 0.8% of the company's stock are short sold.
View CalciMedica's Short Interest.

When is CalciMedica's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CALC earnings forecast.
How do I buy shares of CalciMedica?: Shares of CALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CALC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

CalciMedica (CALC) Stock Price, News & Analysis

CalciMedica MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About CalciMedica Stock (NASDAQ:CALC)

CALC Stock Price History

CALC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CALC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™